Hubei Goto Biopharm Co.,Ltd.
SZSE:300966.SZ
21.06 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Assets: | |||||||
| Current Assets: | |||||||
| Cash & Cash Equivalents
| 181.974 | 438.418 | 209.914 | 28.964 | 129.664 | 65.114 | 44.069 |
| Short Term Investments
| 0.001 | 15.012 | 0.101 | 0 | 0 | 0 | 15.3 |
| Cash and Short Term Investments
| 181.975 | 453.43 | 210.015 | 28.964 | 129.664 | 65.114 | 44.069 |
| Net Receivables
| 257.34 | 307.399 | 263.098 | 342.587 | 205.881 | 162.555 | 129.976 |
| Inventory
| 396.158 | 432.499 | 371.244 | 200.739 | 243.491 | 194.151 | 102.533 |
| Other Current Assets
| 34.26 | 20.404 | 13.899 | 7.353 | 8.609 | 8.137 | 22.836 |
| Total Current Assets
| 869.732 | 1,213.732 | 858.257 | 579.642 | 587.645 | 429.957 | 299.414 |
| Non-Current Assets: | |||||||
| Property, Plant & Equipment, Net
| 1,391.876 | 611.572 | 257.755 | 198.105 | 201.237 | 166.551 | 167.054 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 50.995 | 43.138 | 27.82 | 21.057 | 21.385 | 13.393 | 13.698 |
| Goodwill and Intangible Assets
| 50.995 | 43.138 | 27.82 | 21.057 | 21.385 | 13.393 | 13.698 |
| Long Term Investments
| 48.235 | 33.069 | 14.37 | 0 | 0 | 0 | 0 |
| Tax Assets
| 22.622 | 16.907 | 8.822 | 3.435 | 3.805 | 2.8 | 2.138 |
| Other Non-Current Assets
| 64.281 | 149.899 | 44.219 | 2.187 | 3.61 | 2.377 | 1.031 |
| Total Non-Current Assets
| 1,578.009 | 854.586 | 352.987 | 224.784 | 230.036 | 185.121 | 183.922 |
| Total Assets
| 2,447.741 | 2,068.317 | 1,211.243 | 804.427 | 817.681 | 615.078 | 483.335 |
| Liabilities & Equity: | |||||||
| Current Liabilities: | |||||||
| Account Payables
| 532.237 | 205.523 | 138.173 | 74.118 | 134.218 | 94.128 | 94.902 |
| Short Term Debt
| 132.816 | 328.849 | 154.876 | 139.765 | 147.321 | 80.896 | 55.95 |
| Tax Payables
| 4.084 | 7.485 | 11.403 | 8.257 | 9.139 | 9.819 | 7.308 |
| Deferred Revenue
| 16.598 | 18.956 | 22.565 | 12.52 | 13.38 | 14.277 | 22.932 |
| Other Current Liabilities
| 4.756 | 22.639 | 17.567 | 20.725 | 1.624 | 1.464 | 2.855 |
| Total Current Liabilities
| 686.406 | 575.968 | 333.182 | 247.127 | 296.542 | 190.765 | 176.639 |
| Non-Current Liabilities: | |||||||
| Long Term Debt
| 652.913 | 441.453 | 6.665 | 1.312 | 31.512 | 8.044 | 0 |
| Deferred Revenue Non-Current
| 84.327 | 69.705 | 42.981 | 7.69 | 8.375 | 8.013 | 6.244 |
| Deferred Tax Liabilities Non-Current
| 0.289 | 0.002 | 0 | -1.312 | -31.512 | -8.044 | 0 |
| Other Non-Current Liabilities
| 0.03 | 0.049 | 0 | 9.762 | 31.512 | 8.044 | 0 |
| Total Non-Current Liabilities
| 737.559 | 511.209 | 49.646 | 17.452 | 39.887 | 16.057 | 6.244 |
| Total Liabilities
| 1,423.965 | 1,087.177 | 382.828 | 264.579 | 336.429 | 206.822 | 182.883 |
| Equity: | |||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Common Stock
| 115.279 | 115.277 | 115.277 | 86.277 | 86.277 | 86.277 | 82.006 |
| Retained Earnings
| 320.341 | 297.319 | 272.809 | 197.359 | 145.484 | 76.16 | 54.328 |
| Accumulated Other Comprehensive Income/Loss
| 96.494 | 106.368 | 9.861 | 6.981 | 5.567 | 1.895 | 9.444 |
| Other Total Stockholders Equity
| 420.636 | 409.106 | 409.106 | 243.924 | 243.924 | 243.924 | 154.674 |
| Total Shareholders Equity
| 952.75 | 928.07 | 807.053 | 534.54 | 481.252 | 408.255 | 300.453 |
| Total Equity
| 1,023.776 | 981.141 | 828.415 | 539.847 | 481.252 | 408.255 | 300.453 |
| Total Liabilities & Shareholders Equity
| 2,447.741 | 2,068.317 | 1,211.243 | 804.427 | 817.681 | 615.078 | 483.335 |